The Pathway Discovery group with Neurology Research at Biogen is seeking a talented and enthusiastic cell biologist with a background in neurobiology to join a dynamic team focused on developing disease therapies utilizing Drosophila models.
- PhD in Neurobiology/molecular biology/Cell Biology is a requirement.
- The successful candidate will have a strong track record in neuroscience and/or neurology research demonstrated by high-impact publications
- Proficiency in molecular, histological and cell biological techniques is essential
- Experience in techniques such as qPCR, IHC, molecular biology, microscopy is essential
- Mouse experience preferred, but not required
- The successful candidate will show a clear motivation for using discovery research as a basis for development of effective treatments for neurodegenerative diseases
- The focus of the position will be to develop cell based assays involved in neurodegenerative diseases, such as ALS and PD, in vertebrate and invertebrate cell-based systems to elucidate mechanism of action of candidate targets.
- The successful candidate must have a PhD in the Biological sciences, and will be charged with developing high content assays that will be used to validate genes and pathways identified in genetic screens that affect neurodegeneration.
- He/she will benefit from a rich and growing set of technological resources across Biogen. The ideal candidate will have previous experience using cell based methods to investigate neurodegeneration as well as a working familiarity with one or more of the following: autophagy, unfolded Protein response, RNA biology, ER-stress. Experience in techniques such as qPCR, IHC, molecular biology, microscopy is essential.
- The position is part of a larger team that works on using model systems to understand neurodegeneration, but the candidate should be able to perform independent work.
Candidates who meet the requisite qualifications above click the above official link to Apply.
Biogen (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers innovative therapies to improve the lives of patients with neurodegenerative diseases, hematologic conditions and autoimmune diseases. Patients worldwide benefit every day from our medicines for multiple sclerosis (MS) and hemophilia.
Founded in 1978, Biogen is one of the world’s oldest biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for patients suffering from diseases with few or no treatment options. These include programs for secondary progressive MS, Alzheimer’s Disease, spinal muscular atrophy, lupus and amyotrophic lateral sclerosis (ALS), amongst others.
With approximately 7,500 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.